Marburg virus vaccine safe in small, first-in-human clinical trial: NIH
A study published in the Lancet on January 28 shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. Read More
HBV vaccine developer Hookipa Pharma granted $5 million milestone payment under agreement with Gilead
Hookipa Pharma, the developer of a new class of immunotherapies using an arenavirus platform, on Wednesday announced that it has been granted a $5 million milestone payment under a collaboration agreement with Gilead Sciences. Read More
Ebola vaccine protocols found safe for all ages
Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all regimens were safe in both age groups. The research, published last week in the New England Journal of Medicine, was conducted under the international consortium Partnership for Research on Ebola Vaccination (PREVAC). Read More
Plant offers potential for massive scale production of COVID-19 tests, vaccines
Viral antigen-based diagnostic tests as well as various vaccines have been key tools in fighting COVID-19. Read More
Adjuvanted liposomal vaccine protects baby mice from RSV, looks promising for human newborns
After a more than 50-year wait, a vaccine to protect infants from respiratory syncytial virus (RSV) -- the leading global cause of death in children under age five -- could finally become a reality. A single dose of an adjuvanted liposomal vaccine formulation has induced protection against RSV infection in baby mice. Read More
Current COVID-19 boosters provide protections against serious infection: study
Despite the evolution of the SARS-CoV-2 pandemic coronavirus, a new laboratory study conducted by a team of international researchers suggests current vaccine boosters may elicit sufficient immune protection against severe omicron-induced COVID-19 disease. Read More
NIH-funded research yields promising results for potential universal flu vaccines
A study funded by the National Institutes of Health (NIH) has shown that a new universal flu vaccine offers broad protection against different strains and subtypes of influenza A virus infections. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
